Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

Shorla Oncology

Team Shorla Oncology complete 100k in 30 days for Breast Cancer

March 7th 2022June 30th 2021

Read More

Logo

PharmaVoice Women of the Week – Podcast

March 7th 2022June 2nd 2021

Read More

Logo

Shorla Oncology scores an expedited review for its mystery candidate to treat T-cell malignancies

March 7th 2022April 23rd 2021

Read More

Shorla Oncology

FDA filing acceptance and priority review received for SH-111

March 7th 2022April 23rd 2021

Read More

Logo

United Conference of Generics, Vaccines and Biosimilars

May 14th 2021April 9th 2021

Read More

Logo

30 % Club Ireland

March 7th 2022March 24th 2021

Read More

Logo

Female-Founded Irish Tech Companies Raise Record €105M

April 19th 2021March 8th 2021

Read More

Photo

Shorla Oncology Announces Chief Commercial Officer

March 7th 2022March 2nd 2021

Read More

Logo

The company targeting unmet needs in oncology

April 19th 2021February 25th 2021

Read More

Older posts
Newer posts
Page1 … Page14 Page15 Page16 … Page19
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.